ClinicalTrials.gg
RecruitingNCT07946094Evaluation ofUpdated Nov 18, 2026

Evaluation of the Effect of Comprehensive Myopia Control Interventions on Myopia Prevention and Control

An interventional study of comprehensive myopia control interventions in Myopia and Childhood Myopia, sponsored by Beijing Tongren Hospital. Recruiting at 1 site in China. Open to participants aged 6 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Beijing Tongren Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Aug 2025, registered Nov 2026).
  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
6 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 22 studies in Myopia by Beijing Tongren Hospital — 11 open to participants now, 12 under way, none of them phase 3. Myopia · Beijing Tongren Hospital.

Planned enrollment
3rd of 17
300 · median 120
Started
2025
with 1 other
No phase
14 of 22
7 open now
Primary completion
2027-11
later than 9 of 11 live
Registered
22nd of 22
by date

Among the 22 studies in Myopia by Beijing Tongren Hospital, this one is the 3rd largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 with no phase, reaches primary completion later than 9 of the 11 other live ones, and was the 22nd registered.

Myopia

1,163 studies on the registry are indexed under Myopia; 227 are open to participants now.

Browse Myopia studies →

Open to participants now

11 of the 22 studies in Myopia by Beijing Tongren Hospital are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 120 Myopia studies recruiting now, 19 (16%) set no upper age limit and 100 (83%) stop at 75 or younger; 84 take children under 18; 52 take healthy volunteers.

This study: 6 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Myopia by Beijing Tongren Hospital, or all of them as a file.
02

Study summary

This is a single-center, single-arm, open-label interventional study to evaluate the efficacy of a comprehensive myopia-control regimen in delaying axial elongation and myopia progression in children aged 6-16 years. (Principal investigator: Zhenfei Yang from the Rehabilitation Hospital Affiliated to the National Research Center for Rehabilitation Technical Aids ). The regimen combines five components: (1) myopia-control spectacle lenses incorporating defocus design and Diffusion Optics Technology (DOT); (2) reading-writing glasses that optically relocate near targets to a virtual distance, reducing accommodative lag; (3) nutritional supplements (DHA/EPA, anthocyanins, astaxanthin, vitamin D3 and lutein); (4) repeated low-level red-light (RLRL, 650 nm) therapy; and (5) a distance-viewing device that projects near images to distance. A total of 300 children with myopia will be enrolled and followed for 12 months. The primary outcomes are the change in axial length and the change in cycloplegic spherical equivalent refraction from baseline to 12 months. Safety is monitored throughout by recording adverse events.

Read the detailed description

Rationale: Myopia prevalence in children is rising globally. Single interventions such as defocus spectacle lenses can slow myopia progression by approximately 40%; reading-writing glasses and distance-viewing devices reduce accommodative lag by optically relocating near targets to distance; nutritional supplements may improve choroidal blood supply and scleral oxygenation, thereby increasing scleral resistance to elongation; and repeated low-level red-light (RLRL) therapy at 650 nm may activate mitochondrial cytochrome c oxidase, enhance retinal pigment epithelium energy metabolism and promote dopamine release, inhibiting axial elongation. This study evaluates whether a combination of these approaches yields better myopia-control efficacy than single measures.

Design and procedures: Eligible children aged 6-16 years with myopia will receive the combined regimen for 12 months, including myopia-control spectacle lenses (defocus + DOT), reading-writing glasses for near work, daily nutritional supplements (DHA/EPA, anthocyanins, astaxanthin, vitamin D3, lutein), RLRL sessions (650 nm, per device instructions), and a distance-viewing device during study-related near tasks. Follow-up visits include ocular examinations, axial length measurement, and cycloplegic refraction. Adverse events are recorded and reported to the institutional ethics committee.

03

Conditions studied

  • Myopia
  • Childhood Myopia

Browse trials for

04

Who can participate

Ages eligible
6 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 6-16 years, of either sex;
  2. Myopia in at least one eye, defined as spherical equivalent refraction (SER) between -0.50 D and -6.00 D measured by comprehensive optometry;
  3. Astigmatism no more than 2.50 D;
  4. Corrected visual acuity ≥ 4.9 ;
  5. No prior use of orthokeratology (OK) lenses, red-light therapy, atropine, or remote-image screens for myopia control; prior use of defocus spectacle lenses is permitted;
  6. Signed by guardians and assent by the child (where applicable).

Exclusion criteria

Exclusion Criteria:

  • 1. History of any prior myopia-control treatment other than defocus spectacle lenses (orthokeratology, red-light therapy, atropine, remote-image screens, etc.); 2. Strabismus, amblyopia, or other ocular diseases that may affect visual development or measurements (e.g., congenital cataract, glaucoma, retinal or optic nerve disease); 3. Systemic diseases that may affect vision or participation (e.g., diabetes, connective tissue disease, developmental disorders); 4. Inability to comply with the follow-up schedule or use of the intervention devices; 5. Any other condition judged by the investigator as unsuitable for enrollment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    comprehensive myopia control interventions

    Participants receive the combined regimen consisting of the five interventions listed below for 12 months

    Other: comprehensive myopia control interventions

  • Placebo comparator
    control

    spectacle lenses

    Other: comprehensive myopia control interventions

Interventions

  • Othercomprehensive myopia control interventions

    Participants receive the combined regimen consisting of the five interventions listed below for 12 months

06

What researchers measure

Primary outcomes

  1. Change in axial length from baseline to 12 months

    Axial length measured by optical biometry (IOL Master) at baseline and at 12 months; the change (mm) over 12 months is the primary measure of myopia-control efficacy.

    Time frame: Baseline and 12 months

07

Study locations

1 of 1 sites recruiting
  • Rehabilitation Hospital Affiliated to the National Research Center for Rehabilitation Technical Aids
    Beijing, None Selected 100730, China
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Nov 2027, 27 months after the start.

Of 200 non-industry interventional studies with no phase under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 27 months is close to that.

Counting every sponsor, half of 434 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 18, 2026
StartActual
Aug 13, 2025
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07946094
Collaborators
National Research Center for Rehabilitation Technical Aids
Responsible party
cao kai (Mr, Beijing Tongren Hospital) — Principal investigator
First posted
Nov 18, 2026
Start date
Aug 13, 2025
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion